MAPS Rec'd PCT/PTO 12 MAY 2006

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 839960120 US 12 May 2006
Express Mail Label Number Date of Deposit

Form PTO- (REV 10-9)		i. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER ON-4-33227A					
	TRANSMITTAL LETTER TO		U.S. APPLICATION NO. (if known, see 37 CFR 1.5)					
DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371								
INTER	NATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED					
PCT/E	P04/006317	13 June 2003 (13.06.03)						
	OF INVENTION NOPYRIMIDINE DERIVATIVES AS R	AE KINIASE INHIBITODS	•					
	CANT(S) FOR DO/EO/US	AF KINASE INHIBITORS						
BATT	• •							
Applica	nt herewith submits to the United States D	Designated/Elected Office (DO/EO/US) the	ne following items and other information:					
5.	This is a SECOND or SUBSEQUENT so This express request to begin national examination until the expiration of the ap A proper Demand for International Prelindate. A copy of the International Application as is transmitted herewith (required b. has been transmitted by the Intection of the International Application A translation of the International Applica Amendments to the claims of the International Applica Amendments to the company of the International Amendments to International Amendments to International Amendments to International Amendments to Internation	copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) is not required, as the application was filed in the United States Receiving Office (RO/US). ranslation of the International Application into English (35 U.S.C. 371(c)(2)). nendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). are transmitted herewith (required only if not transmitted by the International Bureau). have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. ranslation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). ranslation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C.						
Items 1	1. to 16. below concern document(s) of	r information included.						
11.	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12. 🗌	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13.	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.							
14.	An Application Data Sheet under 37 CFR 1.76.							
15. 🗌	A substitute specification.							
16. 🗌	A change of power of attorney and/or address letter.							
17. 🛛	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.							
18. 🗌	A second copy of the published International Application under 35 U.S.C. 154(d)(4).							
19. 🗌	A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).							
20. 🛚	Other items or information: copy of Notifipaper copy of sequence listing.	fication of Missing Requirements, submis	ssion of sequence listing statement, and					

	U.S. APPLICATIO 10/560,352	N NO. (if known,	see 37 CFR 1.5)		ERNATIONAL APPLICATION CT/EP04/006317	N NO.			ON-4-332		OCKET NUMBER		
	The following fees are submitted: '.									ULATIO	NS PTO USE		
										ONLY			
	21. E	Basic national fee						\$					
	22. Examin	ation Fee			The state of the s								
					on report was prepa				œ				
	. a	na ali ciain	ns satisty pro	ovisions of Po	CT Article 33(1)-(4)				\$				
	A	All other situations											
		 Search fee If Search fee (37 CFR 1.445(a)(2)) has been paid on the international 											
	a	application to the USPTO as an International Searching Authority\$											
		If International Search Report was prepared and provided to the Office											
	· · · · · · · · · · · · · · · · · · ·									-			
				TOTAL (OF 21, 22 AND 23 =	:				\$	0		
	Additional fe	e for specif	fication and	drawings file	in paper over 100	sheets (exclud	ling sequ	uence listing	or comp	outer		
	program listi thereof.	ng tiled in a	an electronic	medium). T	he fee is \$250 for ea	acn addi	tional	50 shee	ts of paper o	or traction	n		
	Total Sheet	s Extr	a sheets		each additional 50 d		n	R	ATE			***************************************	
	- 100) =	/50 =	thereof (rou	ınd up to a whole nı	umber)	-	X \$	250	\$			
								•		†			
					aration later than 7 CFR 1.492(e)).	⊠ 30				\$	130		
	CLAI		NUMB	ER FILED	NUMBER EX	ΓRA		RA	ŢΕ				
	Total claims	-1-:		- 20 =			X	\$	50	\$			
	Independent		L. NT CLAIM(S				_ <u>X</u>	\$ \$	200 360	\$			
	WOLTH EE I	JEI ENDEI	11 OLYMINGO	/ (ii applicabl	TOTAL OF A	BOVE		<u>_</u>			130		
		Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be iled (Note 37 CFR 1.9, 1.27, 1.28).											
	filed (Note 3					\$ \$	130						
	Processing f	SUBTOTAL = Processing fee of \$130 for furnishing the English translation later than				Ψ	130						
	earliest clain	earliest claimed priority date (37 CFR 1.492(f)). +				\$							
		TOTAL NATIONAL FEE =				\$	130						
		Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +					 \$						
	ој ал аррго	TOTAL FEES ENCLOSED =							130				
									nount to	\$			
/20	6 MKAYPAGH O	MKAYPAGH 00000158 190134 10560352				be: re	efunded						
16	7 130.00 PA					C	charged	\$					
	a. A check in the amount of \$ to cover the above fees is enclosed.												
	b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$130 to cover the above fees. A												
	duplicate copy of this form is enclosed.												
	c. A The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.												
		NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.											
		S. (3), mast so med and granted to restore the application to pending status.											
	Send all correspondence to the address associated with Customer No. 001095, which is currently:												
	Lyh for M												
	NIe	Kristin Konzak					1						
		Novartis Attorney for Applicants Corporate Intellectual Property Reg. No. 44,848				1							
	One	One Health Plaza, Building 104 (617) 871-3216											
	East	East Hanover, NJ 07936-1080											



United States Patent and Trademark Office

United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P. Dox 1450 Alexandra, Viginia 22313-1450 www.uspto.gov

U.S. APPLICATION NUMBER NO. FIRST NAMED APPLICANT ATTY. DOCKET NO. 10/560,352 ON-4-33227A **David Bryant Batt**

INTERNATIONAL APPLICATION NO.

PCT/EP04/06317

001095 **NOVARTIS** CORPORATE INTELLECTUAL PROPERTY ONE HEALTH PLAZA 104/3 **EAST HANOVER, NJ 07936-1080**

I.A. FILING DATE PRIORITY DATE 06/11/2004 06/13/2003

CONFIRMATION NO. 6398 371 FORMALITIES LETTER OC000000018480966*

Date Mailed: 04/07/2006

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 12/12/2005
- Copy of the International Search Report filed on 12/12/2005
- Copy of IPE Report filed on 12/12/2005
- Preliminary Amendments filed on 12/12/2005
- U.S. Basic National Fees filed on 12/12/2005
- Priority Documents filed on 12/12/2005

The applicant needs to satisfy supplemental fees problems indicated below.

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the international application number and international filing date.
- To avoid abandonment, a surcharge (for late submission of filing fee, search fee, examination fee or oath or declaration) as set forth in 37 CFR 1.492(h) of \$130 for a non-small entity, must be submitted with the missing items identified in this letter.

SUMMARY OF FEES DUE:

Total additional fees required for this application is \$130 for a Large Entity:

\$130 Surcharge.

DOCKETED FOR: JUNE 12006

SEQUENCE LISTING REQUIRED

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825 (d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821 (e) may be submitted in lieu of a new CRF.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice **MUST** be returned with the response.

SHAKEEL AHMED

Telephone: (703) 308-9140 EXT 208

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/5/0.250	DCT/ED04/06313	ONI 4 22007 A

10/560,352 PCT/EP04/06317 ON-4-33227A

FORM PCT/DO/EO/905 (371 Formalities Notice)